UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(Dd)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of ~~earliest~~Earliest ~~event~~Event ~~reported~~Reported): ~~June~~August 208, 2017

Kite Pharma, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-36508	27-1524986
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2225 Colorado Avenue Santa Monica, California		90404
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (310) 824-9999

(Registrant’s telephone number, including area code)

Not Applicable

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since ~~Last~~last ~~Report~~report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ~~Emerging growth company ☐~~

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.~~07.~~02 ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

On ~~June~~August 208, 2017, Kite Pharma, Inc. (~~the~~ “~~Company~~Kite”) ~~held~~announced its ~~Annual~~financial ~~Meeting~~results offor ~~Stockholders at~~ the ~~Company’s~~second ~~offices,~~quarter ~~located~~ended ~~at 689 Fifth Avenue~~June 30, ~~14th~~2017 ~~Floor, New York, New York 10022 at 8:00 a.m. local time (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described~~ in ~~more detail in~~ the ~~Company’s definitive proxy statement on Schedule 14A filed with the U.S.~~press ~~Securities~~release ~~and~~attached ~~Exchange~~hereto ~~Commission~~as onExhibit ~~April 28, 2017~~99.1 ~~The following is a brief description of each matter voted upon,~~ and ~~the~~incorporated ~~certified~~herein ~~results,~~by ~~including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter~~reference.

~~Proposal~~The information in this Item 2.02, including the attached Exhibit 99.1:, ~~Election~~is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be ~~Directors~~deemed incorporated by reference in any filing made by Kite under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

~~Each~~Item of the three nominees for Class III directors was elected to serve on the Company’s Board of Directors (the “Board”) until the Annual Meeting of Stockholders in 2020 or until his respective successor has been duly elected or qualified9.01 ~~The~~Financial ~~voting~~Statements ~~results~~and ~~were as follows:~~ Exhibits.

Director Name	Votes For		VotesWithheld		BrokerNon-Votes
Mr. Franz B. Humer		35,363,841		1,091,692		9,798,105
Mr. Joshua A. Kazam		34,737,961		1,717,572		9,798,105
Mr. Steven B. Ruchefsky		35,396,190		1,059,343		9,798,105

(d) Exhibits.

~~Proposal~~The 2:following ~~Ratification~~exhibit ofis ~~Selection~~filed as part of ~~Independent~~this ~~Registered~~Current ~~Public~~Report: ~~Accounting Firm~~

~~The~~99.1 ~~Company’s~~Press ~~stockholders~~Release ~~ratified the selection by the Audit Committee~~ of ~~the~~Kite, ~~Board~~dated ofAugust ~~Ernst &Young LLP as the Company’s independent registered public accounting firm for the year ending December 31~~8, 2017. ~~The voting results were as follows:~~

Votes For		Votes Against		Abstentions		BrokerNon-Votes
45,316,543		910,615		26,480		0

SIGNATURES

~~Proposal~~Pursuant 3:to ~~Consideration~~the requirements of ~~Stockholder~~the ~~Proposal~~Securities ~~Entitled~~Exchange ~~“Elect~~Act ~~Each~~of ~~Director~~1934, ~~Annually”~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

The Company’s stockholders approved the stockholder proposal entitled “Elect Each Director Annually.” The voting results were as follows:


Date: August 8, 2017	KITE PHARMA, INC. (Registrant)

	By:	/s/ Paul Jenkinson
	Name:	Paul Jenkinson
	Title:	Chief Financial Officer

Votes For		Votes Against		Abstentions		BrokerNon-Votes
29,423,200		6,964,275		68,058		9,798,105

EXHIBIT INDEX

Proposal 4: Advisory Vote on Executive Compensation


Exhibit Number		Description

99.1		Press Release of Kite, dated August 8, 2017.

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows:

Votes For		Votes Against		Abstentions		BrokerNon-Votes
33,807,832		2,303,501		344,200		9,798,105

Proposal 5: Advisory Vote on the Frequency of Solicitation of Advisory Stockholder Approval of Executive Compensation

The Company’s stockholders approved, on an advisory basis, the frequency of every one year as the frequency preferred by stockholders for the solicitation of advisory stockholder approval of the compensation paid to the Company’s named executive officers. The voting results were as follows:

Votes For 1 Year		Votes For 2 Years		Votes For 3 Years		Abstentions
34,888,458		233,685		911,278		422,112

Consistent with the preference of the Company’s stockholders indicated by the voting results with respect to this proposal, the Company has decided to include an advisory vote on the compensation of the Company’s named executive officers every year until the next required vote on the frequency of stockholder votes on executive compensation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KITE PHARMA, INC. (Registrant)

Dated: June 23, 2017

/s/ Paul Jenkinson

Paul Jenkinson

Chief Financial Officer

Filing Compare · Kite Pharma, Inc.